191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_D72A5BC15636
Type
Autre: use this type when nothing else fits.
Collection
Publications
Institution
UNIL/CHUV
Title
191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC.
Author(s)
Peters S., Antonia S., Goldberg S.B., Heymach J.V., Kim E.S., Nakagawa K., Papadimitrakopoulou V., Mukhopadhyay P., McIntosh S., Rizvi N.A.
ISBN
1556-1380 (Electronic)
ISSN-L
1556-0864
Issued date
2016
Language
english
OAI-PMH
oai:serval.unil.ch:BIB_D72A5BC15636
DOI
10.1016/S1556-0864(16)30300-8
Pubmed
27198327
Open Access
Yes
Create date
06/06/2016 16:26
Last modification date
20/08/2019 15:56
Usage data